Search alternatives:
teer decrease » greater decrease (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
19 a » 19 _ (Expand Search), 19 p (Expand Search)
Showing 61 - 80 results of 41,853 for search '(( 19 a decrease ) OR ( 10 ((((teer decrease) OR (mean decrease))) OR (nn decrease)) ))', query time: 0.60s Refine Results
  1. 61
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  2. 62
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  3. 63
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  4. 64
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  5. 65
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  6. 66
    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.

    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  7. 67
    Baseline patient characteristics across neutralizing monoclonal antibody trials.

    Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  8. 68
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  9. 69
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  10. 70
    Overview of the six original ACTIV-3/TICO trials.

    Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  11. 71
    A T-test mean comparison of pre and post COVID-19 differences for selected variables.

    A T-test mean comparison of pre and post COVID-19 differences for selected variables. by Beshir Bedru Nasir (8218863)

    Published 2024
    Save to List
    Saved in:
  12. 72
    Lung tumor development decreases the proportions of CD103<sup>+</sup>XCR1<sup>+</sup> DC1s.

    Lung tumor development decreases the proportions of CD103<sup>+</sup>XCR1<sup>+</sup> DC1s. by Julyanne Brassard (4117441)

    Published 2021
    Save to List
    Saved in:
  13. 73
    Adjusted means and 95% confidence interval of blood pressure change from baseline to the follow-up in different general or abdominal obesity status change groups.

    Adjusted means and 95% confidence interval of blood pressure change from baseline to the follow-up in different general or abdominal obesity status change groups. by Yi-de Yang (6755798)

    Published 2021
    Save to List
    Saved in:
  14. 74
    Mean amplitude values during a complete 360° rotation for the external oblique muscle.

    Mean amplitude values during a complete 360° rotation for the external oblique muscle. by Christoph Anders (4068499)

    Published 2024
    Save to List
    Saved in:
  15. 75
    Mean amplitude values during a complete 360° rotation for the internal oblique muscle.

    Mean amplitude values during a complete 360° rotation for the internal oblique muscle. by Christoph Anders (4068499)

    Published 2024
    Save to List
    Saved in:
  16. 76
    Mean amplitude values during a complete 360° rotation for the rectus abdominis muscle.

    Mean amplitude values during a complete 360° rotation for the rectus abdominis muscle. by Christoph Anders (4068499)

    Published 2024
    Save to List
    Saved in:
  17. 77
    Search duration decreases with target value and increases with the environment’s probability of containing a reward target.

    Search duration decreases with target value and increases with the environment’s probability of containing a reward target. by Michael R. Traner (11836571)

    Published 2021
    Save to List
    Saved in:
  18. 78
    Correlation coefficient and <i>p</i> value for nationwide, region, and prefecture with significant inverse correlation between number of COVID-19 infections and number of incidents, injuries, and fatalities as a result of traffic collisions.

    Correlation coefficient and <i>p</i> value for nationwide, region, and prefecture with significant inverse correlation between number of COVID-19 infections and number of incidents... by Ryo Shimada (6444365)

    Published 2022
    Save to List
    Saved in:
  19. 79
    (a) Tuberculosis (TB) incidence rate of 90 countries in 1990 and (b) TB mortality rate of 28 countries in 1950, according to the BCG vaccination status in 2015.

    (a) Tuberculosis (TB) incidence rate of 90 countries in 1990 and (b) TB mortality rate of 28 countries in 1950, according to the BCG vaccination status in 2015. by Kazuo Inoue (302545)

    Published 2021
    Save to List
    Saved in:
  20. 80
    Overlap between provinces with an anomalous decrease in hunting licences and excess mortality, for 2020–2021 and 2021–2022.

    Overlap between provinces with an anomalous decrease in hunting licences and excess mortality, for 2020–2021 and 2021–2022. by Jacopo Cerri (6271958)

    Published 2024
    Save to List
    Saved in:

Search Tools: